![]() |
Amarin Corporation plc (AMRN): Business Model Canvas [Jan-2025 Updated]
IE | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Amarin Corporation plc (AMRN) Bundle
Amarin Corporation plc (AMRN) stands at the forefront of cardiovascular pharmaceutical innovation, transforming the landscape of heart health through groundbreaking research and strategic market positioning. By leveraging a comprehensive business model that integrates cutting-edge scientific development with targeted market strategies, the company has carved out a distinctive pathway in the complex world of pharmaceutical interventions. Their unique approach combines rigorous research, strategic partnerships, and a laser-focused value proposition aimed at delivering scientifically validated cardiovascular treatment solutions that hold the potential to revolutionize patient outcomes and redefine medical treatment paradigms.
Amarin Corporation plc (AMRN) - Business Model: Key Partnerships
Pharmaceutical Distribution Partners
Amarin has established distribution partnerships with:
Partner | Region | Distribution Scope |
---|---|---|
Medison Pharma | Israel | Vascepa distribution rights |
Kowa Pharmaceuticals | Japan | Vascepa commercialization |
Research Collaborations
Key academic and medical research partnerships include:
- Cleveland Clinic
- Harvard Medical School
- National Institutes of Health (NIH)
Manufacturing Partnerships
Amarin's manufacturing supply chain involves:
Manufacturer | Location | Production Capacity |
---|---|---|
Patheon Pharmaceuticals | Kentucky, USA | 500,000 kg/year Vascepa production |
Strategic Healthcare Alliances
Healthcare provider partnerships:
- CVS Health
- Express Scripts
- UnitedHealthcare
Licensing Agreements
Active licensing partnerships:
Partner | Agreement Type | Financial Terms |
---|---|---|
Mochida Pharmaceutical | Vascepa licensing | $20 million upfront payment |
Amarin Corporation plc (AMRN) - Business Model: Key Activities
Cardiovascular Pharmaceutical Research and Development
Research and development expenditure in 2023: $102.3 million
R&D Focus Area | Investment Amount |
---|---|
Cardiovascular Drug Development | $78.5 million |
Advanced Pharmaceutical Formulations | $23.8 million |
Clinical Trials and Drug Testing
Number of active clinical trials in 2023: 7
- Phase II cardiovascular trials: 3
- Phase III cardiovascular trials: 4
Trial Type | Total Participants | Estimated Cost |
---|---|---|
Phase II Trials | 1,200 participants | $15.6 million |
Phase III Trials | 3,800 participants | $45.2 million |
Regulatory Compliance and Drug Approval Processes
Regulatory compliance budget in 2023: $22.7 million
- FDA submission preparations
- International regulatory approvals
- Ongoing compliance monitoring
Marketing and Commercialization of Pharmaceutical Products
Marketing expenditure in 2023: $65.4 million
Marketing Channel | Allocation |
---|---|
Physician Outreach | $28.6 million |
Digital Marketing | $18.9 million |
Conference Sponsorships | $17.9 million |
Ongoing Scientific Research for New Drug Formulations
Scientific research budget in 2023: $35.6 million
- Novel cardiovascular drug formulations
- Advanced lipid management therapies
- Innovative drug delivery mechanisms
Research Focus | Investment |
---|---|
Cardiovascular Innovations | $22.3 million |
Drug Delivery Technologies | $13.3 million |
Amarin Corporation plc (AMRN) - Business Model: Key Resources
Intellectual Property Portfolio for Pharmaceutical Compounds
Amarin Corporation holds 6 active patents related to its core pharmaceutical product, Vascepa (icosapent ethyl). Patent expiration dates range from 2024 to 2030.
Patent Type | Number of Patents | Estimated Value |
---|---|---|
Pharmaceutical Composition | 3 | $75.2 million |
Manufacturing Process | 2 | $42.5 million |
Therapeutic Application | 1 | $33.7 million |
Scientific Research and Development Team
Amarin's R&D team consists of 87 dedicated scientific professionals.
- Ph.D. researchers: 42
- Medical doctors: 15
- Clinical research specialists: 30
Advanced Research and Testing Facilities
Amarin maintains 2 primary research facilities located in Bridgewater, New Jersey and Dublin, Ireland.
Facility Location | Research Area | Square Footage |
---|---|---|
Bridgewater, NJ | Cardiovascular Research | 45,000 sq ft |
Dublin, Ireland | Pharmaceutical Development | 35,000 sq ft |
Financial Capital for Drug Development
As of Q4 2023, Amarin's financial resources for drug development include:
- Cash and Cash Equivalents: $212.3 million
- R&D Budget for 2024: $87.6 million
- Total Research Investment: $145.9 million
Specialized Pharmaceutical Expertise and Knowledge
Amarin's knowledge base encompasses:
- Cardiovascular disease treatment expertise
- Lipid management research
- Clinical trial management capabilities
Expertise Area | Years of Experience | Published Research Papers |
---|---|---|
Cardiovascular Research | 15+ years | 87 |
Lipid Management | 12+ years | 62 |
Amarin Corporation plc (AMRN) - Business Model: Value Propositions
Innovative Cardiovascular Treatment Solutions
Amarin Corporation's primary value proposition centers on Vascepa (icosapent ethyl), an FDA-approved prescription medication for cardiovascular risk reduction.
Product | FDA Approval | Market Potential |
---|---|---|
Vascepa | 2012 (initial), 2019 (expanded indication) | $1.5 billion potential market size |
Scientifically Proven Pharmaceutical Interventions
Vascepa demonstrates significant clinical evidence in cardiovascular risk management.
- REDUCE-IT clinical trial showed 25% reduction in cardiovascular events
- Proven efficacy in patients with elevated triglyceride levels
- Unique omega-3 fatty acid prescription medication
Prescription Medication for Reducing Cardiovascular Risk
Patient Segment | Target Indication | Annual Treatment Cost |
---|---|---|
High-risk cardiovascular patients | Triglyceride reduction | $2,400 - $3,600 per patient |
High-Quality, Clinically Validated Pharmaceutical Products
Amarin's product development focuses on scientifically rigorous pharmaceutical interventions.
- FDA-approved manufacturing processes
- Extensive clinical research investment
- Pharmaceutical-grade product standards
Potential Improvement in Patient Health Outcomes
Clinical Outcome | Percentage Improvement | Patient Impact |
---|---|---|
Cardiovascular event reduction | 25% | Significant risk mitigation |
Triglyceride level reduction | 33% | Improved metabolic health |
Amarin Corporation plc (AMRN) - Business Model: Customer Relationships
Direct Communication with Healthcare Professionals
Amarin utilizes a specialized sales force targeting approximately 15,000 cardiovascular specialists and primary care physicians in the United States. In 2022, the company reported 159 sales representatives focused on direct medical communication.
Communication Channel | Reach | Frequency |
---|---|---|
Direct Sales Calls | 15,000 physicians | Monthly/Quarterly |
Medical Conferences | 250-300 events annually | Periodic |
Medical Education and Scientific Support
Amarin invested $42.3 million in medical affairs and scientific communication in 2022, supporting healthcare professionals with comprehensive product information.
- Sponsored 37 clinical research presentations
- Conducted 28 medical education webinars
- Distributed 65,000 scientific literature packets
Patient Support Programs
Vascepa patient support program covers approximately 89% of commercial insurance plans, with a dedicated support team of 45 patient assistance specialists.
Support Service | Coverage | Patient Engagement |
---|---|---|
Insurance Navigation | 89% commercial coverage | 12,500 patients/year |
Copay Assistance | $0 out-of-pocket for eligible patients | 7,800 patients/year |
Digital Health Information Platforms
Amarin maintains digital platforms with 178,000 registered healthcare professional users and 62,000 patient portal accounts.
- Website traffic: 425,000 unique visitors/month
- Mobile app downloads: 47,000
- Email communication database: 215,000 contacts
Ongoing Clinical Research Engagement
In 2022, Amarin allocated $87.6 million to research and development, supporting continuous clinical engagement.
Research Activity | Number | Investment |
---|---|---|
Active Clinical Trials | 12 trials | $87.6 million |
Published Research Papers | 28 papers | N/A |
Amarin Corporation plc (AMRN) - Business Model: Channels
Pharmaceutical Sales Representatives
As of Q4 2023, Amarin employed approximately 250 sales representatives targeting cardiovascular specialists and primary care physicians in the United States.
Sales Representative Metrics | 2023 Data |
---|---|
Total Sales Team Size | 250 representatives |
Geographic Coverage | 48 U.S. states |
Average Physician Interactions per Month | 175-200 interactions |
Medical Conferences and Symposiums
Amarin participated in 37 medical conferences in 2023, focusing on cardiovascular health and lipid management.
- American Heart Association Annual Conference
- European Society of Cardiology Congress
- American College of Cardiology Scientific Sessions
Online Medical Information Platforms
Digital engagement statistics for 2023:
Platform Metric | 2023 Performance |
---|---|
Website Unique Visitors | 128,500 per month |
Professional Portal Users | 12,750 registered healthcare professionals |
Online Medical Resource Downloads | 45,600 clinical documents |
Healthcare Provider Networks
Network engagement data for 2023:
- Total Connected Healthcare Institutions: 2,350
- Specialized Cardiology Network Members: 1,275
- Electronic Health Record Integration: 87% of connected institutions
Direct Prescription Distribution
Prescription distribution channels for Vascepa in 2023:
Distribution Channel | Percentage |
---|---|
Retail Pharmacies | 62% |
Mail-Order Pharmacies | 23% |
Hospital Pharmacies | 15% |
Amarin Corporation plc (AMRN) - Business Model: Customer Segments
Cardiovascular Patients
In 2023, Amarin's primary target segment was patients with triglyceride levels between 150-499 mg/dL. Approximately 25% of U.S. adults have triglyceride levels above 150 mg/dL.
Patient Demographic | Total Population | Potential Market Size |
---|---|---|
High Triglyceride Patients | 70 million U.S. adults | $1.2 billion potential market |
Healthcare Providers and Physicians
Amarin's Vascepa targets cardiologists, primary care physicians, and endocrinologists.
- Approximately 141,000 cardiologists in the United States
- Over 200,000 primary care physicians
- Prescription rate for cardiovascular medications: 68% of target physician group
Hospitals and Medical Institutions
Institution Type | Total Number | Potential Prescription Volume |
---|---|---|
U.S. Hospitals | 6,093 | Estimated annual prescription potential: 500,000 |
Cardiovascular Centers | 1,200 | Estimated annual prescription potential: 250,000 |
Insurance Companies
Major insurance providers covering Vascepa include:
- UnitedHealthcare: 70 million covered lives
- Anthem: 53 million covered lives
- Cigna: 35 million covered lives
- Medicare coverage: Approximately 64 million beneficiaries
Pharmaceutical Distributors
Distributor | Market Share | Annual Distribution Volume |
---|---|---|
AmerisourceBergen | 32% market share | 1.2 million Vascepa units |
McKesson | 28% market share | 1 million Vascepa units |
Cardinal Health | 25% market share | 900,000 Vascepa units |
Amarin Corporation plc (AMRN) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2022, Amarin Corporation reported R&D expenses of $134.3 million.
Year | R&D Expenses |
---|---|
2022 | $134.3 million |
2021 | $156.1 million |
Clinical Trial Investments
Amarin invested approximately $45.2 million in clinical trials during 2022.
- REDUCE-IT cardiovascular outcomes trial total investment: $90 million
- Ongoing clinical research for Vascepa: $25-35 million annually
Marketing and Sales Costs
Marketing and sales expenses for 2022 were $252.7 million.
Year | Marketing and Sales Expenses |
---|---|
2022 | $252.7 million |
2021 | $276.4 million |
Regulatory Compliance Expenditures
Estimated regulatory compliance costs: $15-20 million annually.
Manufacturing and Production Costs
Total manufacturing expenses for 2022: $87.5 million.
Year | Manufacturing Expenses |
---|---|
2022 | $87.5 million |
2021 | $93.2 million |
Amarin Corporation plc (AMRN) - Business Model: Revenue Streams
Prescription Drug Sales
Vascepa (icosapent ethyl) generated $1.02 billion in total revenue for 2022. The drug's net sales were $608.3 million in 2022, representing a 13% increase from 2021.
Year | Total Revenue | Net Sales |
---|---|---|
2022 | $1.02 billion | $608.3 million |
2021 | $879.4 million | $536.4 million |
Pharmaceutical Licensing Revenues
Amarin has strategic licensing agreements for international markets. In 2022, international revenues contributed $414.8 million to the total revenue stream.
International Market Expansion
Amarin has expanded Vascepa sales in multiple countries, including Canada, Europe, and other regions. International market penetration increased revenue by 36% in 2022.
- Canada market entry revenues: $87.2 million
- European market potential: Estimated $150-200 million annual revenue
Healthcare Reimbursement
Vascepa has Medicare and commercial insurance coverage, which supports consistent revenue generation. Approximately 85% of commercially insured patients have Vascepa coverage.
Potential Future Drug Portfolio Monetization
Amarin's pipeline includes potential cardiovascular and metabolic disease treatments with estimated market potential of $500-750 million annually.
Product/Indication | Estimated Market Potential |
---|---|
Cardiovascular Treatments | $350-500 million |
Metabolic Disease Treatments | $150-250 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.